ASCO GU: Anticoagulant Use Predicts Metastatic Prostate CA Survival

This article originally appeared here.
Share this content:
ASCO: Anticoagulant Use Predicts Metastatic Prostate CA Survival
ASCO: Anticoagulant Use Predicts Metastatic Prostate CA Survival

(HealthDay News) -- Anticoagulant use is associated with improved overall survival in men receiving docetaxel chemotherapy for treatment of metastatic castration-resistant prostate cancer (mCRPC), according to research presented at the American Society of Clinical Oncology's annual Genitourinary Cancers Symposium, held from Feb. 14 to 16 in Orlando, Fla.

Caroline F. Pratz, M.S.N., of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, and colleagues retrospectively reviewed the records of 247 consecutive mCRPC patients who received first-line docetaxel chemotherapy (Jan. 1, 1998, to Jan. 1, 2010). The authors sought to ascertain information on anticoagulant use.

The researchers found that 29 of the 247 men (11.7 percent) received anticoagulation therapy (low-molecular-weight [LMW] heparin, 17; warfarin, 12). Anticoagulation therapy was indicated for deep venous thrombosis (DVT) in 15 of the 247 men, pulmonary embolism (PE) in nine, and both DVT and PE in five. Anticoagulant use was associated with significantly improved overall survival (any anticoagulant HR, 0.61; P = 0.024; LMW heparin HR, 0.58; P = 0.048; warfarin HR, 0.82; P = 0.23). For use of any anticoagulant, median overall survival was 20.9 months, compared to 17.1 months without an anticoagulant. After adjusting for other prognostic factors, anticoagulant use remained a significant predictor of overall survival.

"If validated, these data may provide the impetus to explore the antitumor potential of anticoagulants in prospective clinical trials," the authors write.

More Information

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs